Advertisement

Esophageal Cancer

  • Di Martino Natale
  • Monaco Luigi
Chapter

Abstract

Esophageal cancer is still the leading cause of cancer-related death in the world, but although in the last few decades, there has been an increase in long-term survival for these tumors, it still stands altogether at around 20% at 5 years for patients treated, and, unfortunately, more than 50% of the patients who come to observation present with locally advanced or non-resectable tumors. The aging population and a longer life expectancy have led to a significant increase of elderly patients being referred for treatment. For many patients, and particularly for esophageal cancer, surgery is still the main treatment, and esophagectomy is the major surgical procedure. Although burdened by a high incidence of morbidity and mortality, the effect of age on the outcome of these patients is still controversial.

The improvement of anesthetic techniques and postoperative pain control, especially the introduction into clinical practice of assessing the fragility of the elderly patient, has allowed, even in aggressive treatment protocols, a growing number of elderly patients to enlist with results, in terms of morbidity and mortality, similar to those of younger patients.

Proper treatment planning for cancer of the esophagus is influenced by numerous factors (staging, grading, and performance status of patients). The most appropriate treatment protocol must take into account, first of all, the involvement of the wall that appears to be strongly associated with the presence of lymph node involvement and distant metastases in order to plan the most appropriate therapeutic approach which would guarantee the best results in terms of morbidity and survival rate in relation to the patient’s performance status.

The combined use of chemotherapy and radiotherapy, unlike the neoadjuvant trimodality therapy, showed that this protocol is important to understage disease with pathological complete response (pCR) ranging from 20 up to 40%. For these reasons the multimodality therapy has become the foundation for treatment of the majority of patients with cancer of the esophagus and cardias. The treatment approach depends on several factors and requires a team of specialists.

Keywords

Squamous cell carcinoma Adenocarcinoma of the esophagus Cardia Therapy SCC EAC Elderly 

References

  1. 1.
    Fentiman IS, Tirelli U, Monfardini S, Schneider M, Festen J, Cognetti F, Aapro MS. Cancer in the elderly: why so badly treated? Lancet. 1990;335(8696):1020–2.CrossRefGoogle Scholar
  2. 2.
    O’Connel JB, Maggard MA, Ko CY. Cancer-direct surgery for localized disease: decreased use in the elderly? Ann Surg Oncol. 2004 Nov;11(11):962–9.CrossRefGoogle Scholar
  3. 3.
    Internullo E, Moons J, Nafteux P, Coosemans W, Decker G, De Leyn P, et al. Outcome after esophagectomy for cancer of the esophagus and GEJ in patients aged over 75 years. Eur J Cardiothorac Surg. 2008;33:1096–104.CrossRefPubMedGoogle Scholar
  4. 4.
    Walter LC, et al. Cancer screening in elderly patients a framework for individualized decision making. JAMA. 2001;285:2750–6.CrossRefGoogle Scholar
  5. 5.
    Ruol A, Portale G, Zaninotto G, Cagol M, Cavallin F, Castoro C, et al. Results of esophagectomy for esophageal cancer in elderly patients: age has little influence on outcome and survival. J Thorac Cardiovasc Surg. 2007;133:1186–92.CrossRefPubMedGoogle Scholar
  6. 6.
    Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin. 2012;62:118–28.CrossRefPubMedGoogle Scholar
  7. 7.
    Bosetti C, Levi F, Ferlay J, et al. Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer. 2008;122:1118–29.CrossRefPubMedGoogle Scholar
  8. 8.
    Falk GW. Risk factors for esophageal cancer development. Surg Oncol Clin N Am. 2009;18:469–85.CrossRefPubMedGoogle Scholar
  9. 9.
    Pickens A, Orringer MB. Geographical distribution and racial disparity in esophageal cancer. Ann Thorac Surg. 2003;76:S1367–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Pandeya N, Olsen CM, Whiteman DC. Sex differences in the proportion of esophageal squamous cell carcinoma cases attributable to tobacco smoking and alcohol consumption. Cancer Epidemiol. 2013;37:579–84.CrossRefPubMedGoogle Scholar
  11. 11.
    Pandeya N, Williams G, Green AC, Webb PM, Whiteman DC, Australian CS. Alcohol consumption and the risks of adenocarcinoma and squamous cell carcinoma of the esoph- agus. Gastroenterology. 2009;136:1215–24. e1211ee1212CrossRefPubMedGoogle Scholar
  12. 12.
    Lindkvist B, Johansen D, Stocks T, et al. Metabolic risk factors for esophageal squamous cell carcinoma and adenocarcinoma: a prospective study of 580,000 subjects within the me-can project. BMC Cancer. 2014;14:103.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Bosetti C, Levi F, Ferlay J, et al. Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer. 2008;122:1118–29.CrossRefPubMedGoogle Scholar
  14. 14.
    Monaco L, Brillantino A, Torelli F, Schettino M, Izzo G, Cosenza A, Di Martino N. Prevalence of bile reflux in gastroesophageal reflux disease patients not responsive to proton pump inhibitors. World J Gastroenterol. 2009;15(3):334–8.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Nason KS, Wichienkuer PP, Awais O, et al. Gastro- esophageal reflux disease symptom severity, proton pump inhibitor use, and esophageal carcinogenesis. Arch Surg. 2011;146:851–8.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Corley DA, Kubo A, Zhao W. Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomark Prev. 2008;17:352–8.CrossRefGoogle Scholar
  17. 17.
    Brillantino A, Monaco L, Schettino M, Torelli F, Izzo G, Cosenza A, Marano L, Di Martino N. Prevalence of pathological duodenogastric reflux and the relationship between duodenogastric and duodenogastrooesophageal reflux in chronic gastrooesophageal reflux disease. Eur J Gastroenterol Hepatol. 2008;20(12):1136–43.CrossRefPubMedGoogle Scholar
  18. 18.
    Hoyo C, Cook MB, Kamangar F, et al. Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the international BEA- CON consortium. Int J Epidemiol. 2012;41:1706–18.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Cook MB, Kamangar F, Whiteman DC, et al. Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst. 2010;102:1344–53.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Ma J-Y, Wu Z, Wang Y, Zhao Y-F, Liu L-X, Kou Y-L, Zhou Q-H. Clinicopathologic characteristics of esophagectomy for esophageal carcinoma in elderly patients. World J Gastroenterol. 2006;12(8):1296–9.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Monson K, et al. Surgery in the aged population. Arch Surg. 2003;138(10):1061–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Feder G, Cryer C, Donovan S, Carter Y. Guidelines for the prevention of falls in people over 65. The Guidelines’ development group. BMJ. 2000;321:1007–11.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Robinson TN, et al. Simple frailty score predicts post-operative complications across surgicall specialties. Am J Surg. 2013;206(4):544–50.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Young PE, Gentry AB, Acosta RD, et al. Endoscopic ultrasound does not accurately stage early adenocarcinoma or high-grade dysplasia of the esophagus. Clin Gastroenterol Hepatol. 2010;8:1037–41.CrossRefPubMedGoogle Scholar
  25. 25.
    Smith BR, Chang KJ, Lee JG, et al. Staging accuracy of endoscopic ultrasound based on pathologic analysis after minimally invasive esophagectomy. Am Surg. 2010;76:1228–31.PubMedGoogle Scholar
  26. 26.
    Rebollo Aguirre AC, Ramos-Font C, Villegas Portero R, et al. 18F- fluorodeoxiglucose positron emission tomography for the evaluation of neoadjuvant therapy response in esophageal cancer: systematic review of the literature. Ann Surg. 2009;250:247–54.CrossRefPubMedGoogle Scholar
  27. 27.
    Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta- analysis. Lancet Oncol. 2011;12:681–92.CrossRefPubMedGoogle Scholar
  28. 28.
    Bonavina L, Bona D, Binyom P, Peracchia A. A laparoscopy-assisted surgical approach to esophageal carcinoma. J Surg Res. 2004;117:52–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Luketich JD, Meehan M, Nguyen NT, et al. Minimally invasive surgical staging for esophageal cancer. Surg Endosc. 2000;4:700.CrossRefGoogle Scholar
  30. 30.
    Baisi A, Bonavina L, Peracchia A. Bronchoscopic staging of squamous cell carcinoma of the upper thoracic esophagus. Arch Surg. 1999;132:140–3.CrossRefGoogle Scholar
  31. 31.
    Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85:1457–9.CrossRefGoogle Scholar
  32. 32.
    Edge SB, American Joint Committee on Cancer, Amer- ican Cancer Society. AJCC cancer staging handbook from the AJCC cancer staging manual. New York: Springer; 2010.Google Scholar
  33. 33.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.CrossRefGoogle Scholar
  34. 34.
    Al-Sarraf M, Martz K, Herskovic A, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol. 1997;15:277–2.CrossRefGoogle Scholar
  35. 35.
    Philip PA, Ajani JA. Has combined modality therapy improved the outlook in carcinoma of the esophagus? Oncology. 1994;8:37–42.Google Scholar
  36. 36.
    Orditura M, Galizia G, Fabozzi A, Lieto E, Gambardella V, Morgillo F, Del Genio GM, Fei L, Di Martino N, Renda A, Ciardiello F, De Vita F. Preoperative treatment of locally advanced esophageal carcinoma (review). Int J Oncol. 2013;43(6):1745–53.CrossRefGoogle Scholar
  37. 37.
    Van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.CrossRefGoogle Scholar
  38. 38.
    Ajani JA. Current status of new drugs and multidisciplinary approaches in patients with carcinoma of the esophagus. Chest. 1998;113(Suppl):S112–9.CrossRefGoogle Scholar
  39. 39.
    Cools-Lartigue J, Spicer J, Ferri LE. Current status of management of malignant disease: current management of esophageal cancer. J Gastrointest Surg. 2015;19:964–72.CrossRefGoogle Scholar
  40. 40.
    Leers JM, DeMeester SR, Oezcelik A, et al. The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma a retrospective review of esophagectomy specimens. Ann Surg. 2011;253:271–8.CrossRefPubMedGoogle Scholar
  41. 41.
    Semlitsch T, Jeitler K, Schoe R, et al. A systematic review of the evidence for radiofrequency ablation for Barrett’s esophagus. Surg Endosc. 2010;24:2935–43.CrossRefPubMedGoogle Scholar
  42. 42.
    Chennat J, Waxman I. Endoscopic treatment of Barrett’s esophagus: from metaplasia to intramucosal carcinoma. World J Gastroenterol. 2010;16:3780–5.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Ell C, May A, Gossner L, et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett’s esophagus. Gastroenterology. 2000;118:670–7.CrossRefPubMedGoogle Scholar
  44. 44.
    May A, Gossner L, Pech O, et al. Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett’s oesophagus: acute-phase and intermediate results of a new treatment approach. Eur J Gastroenterol Hepatol. 2002;14:1085–91.CrossRefPubMedGoogle Scholar
  45. 45.
    Pech O, Bollschweiler E, Manner H, et al. Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett’s esophagus at two high-volume centers. Ann Surg. 2011;254:67–72.CrossRefPubMedGoogle Scholar
  46. 46.
    Sepesi B, Watson TJ, Zhou D, et al. Are endoscopic therapies appropriate for superficial submucosal esophageal adenocarcinoma? An analysis of esophagectomy specimens. J Am Coll Surg. 2010;210:418–27.CrossRefPubMedGoogle Scholar
  47. 47.
    Manner H, May A, Pech O, et al. Early Barrett’s carcinoma with “low-risk” submucosal invasion: long-term results of endoscopic resection with a curative intent. Am J Gastroenterol. 2008;103:2589–97.CrossRefPubMedGoogle Scholar
  48. 48.
    Peters FP, Brakenhoff KP, Curvers WL, et al. Histologic evaluation of resection specimens obtained at 293 endoscopic resections in Barrett’s esophagus. Gastrointest Endosc. 2008;67:604–9.CrossRefPubMedGoogle Scholar
  49. 49.
    Manner H, Pech O, Heldmann Y, et al. Efficacy, safety, and long-term results of endoscopic treatment for early stage adenocarcinoma of the esophagus with low-risk sm1 invasion. Clin Gastroenterol Hepatol. 2013;11:630–5. quiz e45CrossRefPubMedGoogle Scholar
  50. 50.
    Rice TW, Mason DP, Murthy SC, et al. T2N0M0 esophageal cancer. J Thorac Cardiovasc Surg. 2007;133:317–24.CrossRefPubMedGoogle Scholar
  51. 51.
    Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al. Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data. Eur J Cancer. 2013;49:3149–58.CrossRefPubMedGoogle Scholar
  52. 52.
    Markar SR, Karthikesalingam A, Penna M, et al. Assessment of short-term clinical outcomes following salvage esophagectomy for the treatment of esophageal malignancy: systematic review and pooled analysis. Ann Surg Oncol. 2014;21:922–31.CrossRefPubMedGoogle Scholar
  53. 53.
    Teoh AY, Yan Chiu PW, Wong TC, et al. Functional performance and quality of life in patients with squamous esophageal carcinoma receiving surgery or chemoradiation: results from a randomized trial. Ann Surg. 2011;253:1–5.CrossRefPubMedGoogle Scholar
  54. 54.
    Herskovic A, Martz K, Al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radio- therapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593–8.CrossRefPubMedGoogle Scholar
  55. 55.
    Manner H, May A, Rabenstein T, et al. Prospective evaluation of a new high-power argon plasma coagulation system (hp-APC) in therapeutic gastrointestinal endoscopy. Scand J Gastroenterol. 2007;42:397–405.CrossRefPubMedGoogle Scholar
  56. 56.
    Abdel-Wahab M, Gad-Elhak N, Denewer A, et al. Endoscopic laser treatment of progressive dysphagia in patients with advanced esophageal carcinoma. Hepatogastroenterology. 1998;45:1509–15.PubMedGoogle Scholar
  57. 57.
    Alibakhshi A, Aminian A, Mirsharifi R, Jahangiri Y, Dashti H, Karimian F. The effect of age on the outcome of esophageal cancer surgery. Ann Thorac Med. 2009;4(2):71–4.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Greenstein AJ, Litle VR, Swanson SJ, et al. Effect of the number of lymph nodes sampled on postoperative survival of lymph node-negative esophageal cancer. Cancer. 2008;112(6):1239–46.CrossRefPubMedGoogle Scholar
  59. 59.
    Orditura M, Galizia G, Morgillo F, Martinelli E, Lieto E, Vitiello F, Di Martino N, Pacelli R, Renda A, Ciardiello F, De Vita F. Complete response to preoperative chemoradiation and survival in esophageal cancer: a pooled analysis of three single-institution phase II trials. Dis Esophagus. 2012;25(2):130–6.CrossRefPubMedGoogle Scholar
  60. 60.
    Orditura M, Galizia G, Di Martino N, Ancona E, Castoro C, Pacelli R, Morgillo F, Rossetti S, Gambardella V, Farella A, Laterza MM, Ruol A, Fabozzi A, Napolitano V, Iovino F, Lieto E, Fei L, Conzo G, Ciardiello F, De Vita F. Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma-a pilot study. Curr Oncol. 2014;21(3):125–33.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of General and Gastroenterologic surgeryUniversity of Campania “Luigi Vanvitelli”NaplesItaly
  2. 2.General and Laparoscopic SurgeryNursing Home Villa Esther AvellinoAvellinoItaly

Personalised recommendations